Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?
Exact Sciences (NASDAQ: EXAS) and Guardant Health (NASDAQ: GH) make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years, nearly identical high-growth profiles.
Exact Sciences is best known for Cologuard, a non-invasive colorectal cancer screening test that uses stool samples to look for cancerous cells. The company also has tests to detect liver cancer. Its Oncotype DX genomic tests are used by physicians to determine the best treatment options for patients with breast, colon, or prostate cancers.
Guardant uses next-generation genetic sequencing with liquid biopsies to find cancers. Its liquid biopsies search for bits of DNA in a blood sample, and scan them for mutations or other changes connected to cancer.
Source Fool.com
